CRISPR/Cas9 edited, singly expressed HLA class II cells for the study of HLA-DQ immunogenicity

Project: Research project

Project Details

Description

Our overarching goal is to achieve stable transduction of either HLA-DQB1 or HLA-DRB1 into a multiple knockout CRISPR/Cas9 HLA-class II genome edited cell for the purpose of studying HLA-DQ versus HLA-DR specific immune processes including antigen processing and presentation and T cell activation pathways.
To this aim we will:
1. Stably rescue either HLA-DQ or HLA-DR expression in HLA class II knockout cells
2. Demonstrate the ability of the rescued cells to restore T cell allorecognition
3. Demonstrate the ability of the rescued cells to bind either HLA-DQ or HLA-DR specific antibodies
The ability to demonstrate stable, genome edited, 3D appropriate conformation expression of isolated HLA-DQ or HLA-DR molecules, with physiologic characteristics, will provide the required infrastructure to proceed with functional studies interrogating pathways activated by either of these molecules as they participate in different immune processes
StatusActive
Effective start/end date1/1/2112/31/21

Funding

  • Vanguard Charitable Endowment Program (Letter 12/2/2020)

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.